Zivo Bioscience, Inc. (ZIVO) stock
ZIVOOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.80+0.30 (+4.62%)
Close on Oct 19, 2026Market cap $25.96MP/E –Yield –
Zivo Bioscience operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Zivo Bioscience's operating income for the twelve months ending Sep 30, 2025 was -$8.46M. For fiscal 2024 it was -$13.36M. The highest annual figure on record is -$1.94M in fiscal 2011.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$13.36M | – |
| FY2023 | Dec 31, 2023 | -$7.26M | – |
| FY2022 | Dec 31, 2022 | -$8.73M | – |
| FY2021 | Dec 31, 2021 | -$8.65M | – |
| FY2020 | Dec 31, 2020 | -$8.56M | – |
| FY2019 | Dec 31, 2019 | -$8.35M | – |
| FY2018 | Dec 31, 2018 | -$6.13M | – |
| FY2017 | Dec 31, 2017 | -$6.33M | – |
| FY2016 | Dec 31, 2016 | -$3.49M | – |
| FY2015 | Dec 31, 2015 | -$3.06M | – |
| FY2014 | Dec 31, 2014 | -$5.15M | – |
| FY2013 | Dec 31, 2013 | -$3.11M | – |
| FY2012 | Dec 31, 2012 | -$2.08M | – |
| FY2011 | Dec 31, 2011 | -$1.94M | – |
| FY2010 | Dec 31, 2010 | -$4.06M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -$1.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.63M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.21M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.60M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.28M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.90M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.57M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.64M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.07M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.03M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.26M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.67M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.75M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.08M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.76M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.36M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.03M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.41M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.77M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.57M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.04M | – |
| Q1 FY2019 | Mar 31, 2019 | -$967.85K | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.62M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.49M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.34M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.68M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.60M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.06M | – |
| Q2 FY2017 | Jun 30, 2017 | -$881.45K | – |
| Q1 FY2017 | Mar 31, 2017 | -$791.27K | – |
| Q4 FY2016 | Dec 31, 2016 | -$642.66K | – |
| Q3 FY2016 | Sep 30, 2016 | -$677.12K | – |
| Q2 FY2016 | Jun 30, 2016 | -$1.53M | – |
| Q1 FY2016 | Mar 31, 2016 | -$640.56K | – |
| Q4 FY2015 | Dec 31, 2015 | -$663.75K | – |
See a number that looks wrong?